Trials / Recruiting
RecruitingNCT06966024
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Deciphera Pharmaceuticals, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DCC-2812 | Administered orally |
Timeline
- Start date
- 2025-08-27
- Primary completion
- 2029-02-01
- Completion
- 2029-02-01
- First posted
- 2025-05-11
- Last updated
- 2026-02-11
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06966024. Inclusion in this directory is not an endorsement.